Skip to main content
OpenTrials
Completed

NCT Number: NCT01372631

A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

The goal of this research is to further develop novel optical assay systems for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Duke University Medical Center, Durham, North Carolina, United States

Loading trial locations.

About this study

The goal of this research is to further develop novel optical assay systems for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. We are seeking to establish the accuracy of first and second-generation prototypes of technologies utilizing optical spectroscopy for intra operative margin assessment in partial mastectomy or mastectomy specimens. The aims associated with this research are as follows, (1) to evaluate the device-tissue interface on reduction mammoplasty specimens from a total of 20 patients, (2) to assess random and systematic errors of the new miniature system on mastectomy specimens from a total of 40 patients (3) to test the sensitivity, and specificity of the miniature spectral imaging system for margin assessment on excised partial mastectomy or mastectomy specimens from a total of 150 patients undergoing breast conserving surgery.

Last patient's surgery took place in 2017 and recruitment remained open. Later the team encountered staffing issues; therefore the study status was updated to suspended. We recently made the decision to no longer attempt to enroll the remaining 2 subjects and focus on the data analysis only.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing a reduction mammoplasty OR
  • Patients undergoing a lumpectomy mastectomy for the treatment of an invasive or non-invasive breast malignancy
  • Age > 18
  • Clinically detectable disease either by physical examination or radiographic studies
  • Patients of all ethnic and gender groups will be included. Protocol accrual will be reviewed annually to include a determination of minority and gender representation. If accrual demonstrates under-representation of any group with comparison to disease incidence in that group, appropriate measures will be undertaken to increase participation of patients of that minority or gender group
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

  • Patients considered in "vulnerable" populations.

Treatment and study plan

miniature spectral imaging system

Device

Use of miniature spectral imaging system

Bench-top optical spectrometer

Device

Use of bench-top optical spectrometer

High resolution microendoscope

Device

Use of high resolution microendoscope

Primary outcomes

  1. Identification of the optical signatures in breast tissue

    Time frame: Day of procedure (less than 10 minutes)

Secondary outcomes

  1. Sensitivity and Specificity of the device

    Time frame: Day of procedure (less than 10 minutes)

Sponsors and collaborators

Lead sponsor

Duke University

Other

Collaborators

  • National Institute for Biomedical Imaging and Bioengineering (NIBIB)
  • National Institutes of Health (NIH)

Registry information

Important dates

Study start
2011
Primary completion
2017
Study completion
2017
First posted
Jun 14, 2011
Registry last updated
Feb 10, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.